{"filing":{"accession_number":"0001171843-26-004375","cik":"0001574232","ticker":"ADXN","company_name":"Addex Therapeutics Ltd.","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"f6k_063026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1574232/000117184326004375/f6k_063026.htm"},"events":[{"id":14799,"run_id":13190,"accession_number":"0001171843-26-004375","anchor_item_number":"EX-99.1","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This press release announces the results of Addex Therapeutics' 2026 Annual General Meeting, disclosing shareholder approval of all Board proposals including annual financial statements, compensation arrangements, board member re-elections, auditor re-election, and amendments to the Articles of Association. The disclosure explicitly states \"shareholders approved, with a large majority, all proposals\" and itemizes each resolution voted upon, matching the definition of shareholder_vote_results.","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12343,"accession_number":"0001171843-26-004375","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This press release announces the results of Addex Therapeutics' 2026 Annual General Meeting, disclosing shareholder approval of all Board proposals including annual financial statements, compensation arrangements, board member re-elections, auditor re-election, and amendments to the Articles of Association. The disclosure explicitly states \"shareholders approved, with a large majority, all proposals\" and itemizes each resolution voted upon, matching the definition of shareholder_vote_results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-30T10:09:53.306281+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12343,"accession_number":"0001171843-26-004375","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This press release announces the results of Addex Therapeutics' 2026 Annual General Meeting, disclosing shareholder approval of all Board proposals including annual financial statements, compensation arrangements, board member re-elections, auditor re-election, and amendments to the Articles of Association. The disclosure explicitly states \"shareholders approved, with a large majority, all proposals\" and itemizes each resolution voted upon, matching the definition of shareholder_vote_results.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-30T10:09:53.306281+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-06-30"}]}